Hossein Behnammanesh1,2, Mostafa Erfani3,2, Maliheh Hajiramezanali1, Safura Jokar1, Parham Geramifar4, Omid Sabzevari5,6, Mohsen Amini7,8, Seyed Mohammad Mazidi3, Davood Beiki4. 1. Department of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 2. These authors shared first authorship. 3. Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran. 4. Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran. 6. Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran. 7. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 8. Drug Design and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
OBJECTIVES: Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years. The better biomedical properties of radioantagonists as higher tumor uptake make these radioligands more attractive than agonists for somatostatin receptor-targeted radionuclide therapy. In this study, we tried to evaluate the efficiency of Luthetium-177 (177Lu) radiolabeled DOTA-Peptide 2 (177Lu-DOTA-Peptide 2) as a new radioantagonist in HT-29 human colorectal cancer in vitro and in vivo. METHODS: DOTA conjugated antagonistic peptide with the sequence of p-Cl-Phe-Cyclo(D-Cys-L-BzThi-D-Aph-Lys-Thr-Cys)-D-Tyr-NH2 (DOTA-Peptide 2) was labeled with 177Lu. In vitro assays (saturation binding assay and internalization test) and animal biodistribution were performed in human colon adenocarcinoma cells (HT-29) and HT-29 tumor-bearing nude mice. RESULTS: 177Lu-DOTA-Peptide 2 showed high stability in acetate buffer and human plasma (>97%). Antagonistic property of 177Lu-DOTA-Peptide 2 was confirmed by low internalization in HT-29 cells (<5%). The desired dissociation constant (Kd =11.14 nM) and effective tumor uptake (10.89 percentage of injected dose per gram of tumor) showed high binding affinity of 177Lu-DOTA-Peptide 2 to somatostatin receptors. CONCLUSION: 177Lu-DOTA-Peptide 2 demonstrated selective and high binding affinity to somatostatin receptors overexpressed on the surface of HT-29 cancer cells, which could make this radiopeptide suitable for somatostatin receptor-targeted radionuclide therapy.
OBJECTIVES: Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years. The better biomedical properties of radioantagonists as higher tumor uptake make these radioligands more attractive than agonists for somatostatin receptor-targeted radionuclide therapy. In this study, we tried to evaluate the efficiency of Luthetium-177 (177Lu) radiolabeled DOTA-Peptide 2 (177Lu-DOTA-Peptide 2) as a new radioantagonist in HT-29 human colorectal cancer in vitro and in vivo. METHODS: DOTA conjugated antagonistic peptide with the sequence of p-Cl-Phe-Cyclo(D-Cys-L-BzThi-D-Aph-Lys-Thr-Cys)-D-Tyr-NH2 (DOTA-Peptide 2) was labeled with 177Lu. In vitro assays (saturation binding assay and internalization test) and animal biodistribution were performed in human colon adenocarcinoma cells (HT-29) and HT-29 tumor-bearing nude mice. RESULTS: 177Lu-DOTA-Peptide 2 showed high stability in acetate buffer and human plasma (>97%). Antagonistic property of 177Lu-DOTA-Peptide 2 was confirmed by low internalization in HT-29 cells (<5%). The desired dissociation constant (Kd =11.14 nM) and effective tumor uptake (10.89 percentage of injected dose per gram of tumor) showed high binding affinity of 177Lu-DOTA-Peptide 2 to somatostatin receptors. CONCLUSION: 177Lu-DOTA-Peptide 2 demonstrated selective and high binding affinity to somatostatin receptors overexpressed on the surface of HT-29 cancer cells, which could make this radiopeptide suitable for somatostatin receptor-targeted radionuclide therapy.
Authors: Simone U Dalm; Julie Nonnekens; Gabriela N Doeswijk; Erik de Blois; Dik C van Gent; Mark W Konijnenberg; Marion de Jong Journal: J Nucl Med Date: 2015-10-29 Impact factor: 10.057
Authors: Melpomeni Fani; Luigi Del Pozzo; Keelara Abiraj; Rosalba Mansi; Maria Luisa Tamma; Renzo Cescato; Beatrice Waser; Wolfgang A Weber; Jean Claude Reubi; Helmut R Maecke Journal: J Nucl Med Date: 2011-06-16 Impact factor: 10.057
Authors: Guillaume P Nicolas; Rosalba Mansi; Lisa McDougall; Jens Kaufmann; Hakim Bouterfa; Damian Wild; Melpomeni Fani Journal: J Nucl Med Date: 2017-04-27 Impact factor: 10.057
Authors: Damian Wild; Melpomeni Fani; Richard Fischer; Luigi Del Pozzo; Felix Kaul; Simone Krebs; Richard Fischer; Jean E F Rivier; Jean Claude Reubi; Helmut R Maecke; Wolfgang A Weber Journal: J Nucl Med Date: 2014-06-24 Impact factor: 10.057
Authors: E B de Araújo; J S Caldeira Filho; L T Nagamati; E Muramoto; M T Colturato; R M Couto; P B Pujatti; J Mengatti; C P G Silva Journal: Appl Radiat Isot Date: 2008-10-05 Impact factor: 1.513